Ibogaine Import: Hallucinogen Hope or Research Hype?
Published Date: 9/28/2026
Notice
Summary
Benuvia Operations, LLC wants to import a special drug called Ibogaine for research and future medicine testing. People who make or use this drug can share their thoughts or ask for a hearing by October 28, 2026. This move helps Benuvia develop new treatments but doesn’t allow selling finished medicines yet.
Analyzed Economic Effects
3 provisions identified: 2 benefits, 1 costs, 0 mixed.
Application to Import Ibogaine
On August 11, 2026, Benuvia Operations, LLC applied to be registered to import Ibogaine (drug code 7260), a Schedule I controlled substance, to support internal research and development toward bulk manufacture of active pharmaceutical ingredient (API) for future clinical trials. The registration would authorize import of the listed basic class only; no other activity for this drug code is authorized.
No Import of Finished Dosage Forms
The Drug Enforcement Administration states that any authorization will not extend to the import of Food and Drug Administration-approved or non-approved finished dosage forms for commercial sale. Registrants may only import the bulk API activity that is expressly authorized under the registration.
Comment and Hearing Deadline Oct 28, 2026
Registered bulk manufacturers of the affected basic class(es) and applicants may submit electronic comments or objections, or file a written request for a hearing, on or before October 28, 2026. Comments must be submitted via https://www.regulations.gov and hearing requests must be mailed to the DEA addresses listed in the notice.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2025-05007, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
Starting December 31, 2025, veterans can get buprenorphine treatment and follow-up care through telemedicine, making it easier to access help for opioid use disorder without leaving home. This change affects veterans using VA health services and aims to improve treatment access while the government reviews feedback and policies. No new costs are mentioned, but the delay gives agencies time to ensure the rules work well.
2025-02793, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
The government is giving veterans easier access to buprenorphine treatment through telemedicine, letting them get care remotely. This change affects veterans using VA health services and aims to make treatment smoother and more convenient. The new rules were supposed to start February 18, 2025, but now they’ll kick in on March 21, 2025, while the government gathers public feedback.
2026-22843, Proposed Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2027
The DEA is setting limits on how much of certain controlled drugs and chemicals can be made in 2027. This affects drug makers and anyone involved in producing or handling these substances. They’re asking for public comments by December 10, 2026, before finalizing the amounts, which helps keep drug supply safe and balanced.
2026-22842, Adjustment to the 2026 Aggregate Production Quota for d,l-Amphetamine, d-Amphetamine (for Sale), Hydromorphone and Methylphenidate (for Sale) Pursuant to 21 U.S.C. 826(h)
The DEA is boosting the 2026 production limits for four important medicines: d,l-amphetamine, d-amphetamine (for sale), hydromorphone, and methylphenidate (for sale). This change helps fix shortages and keeps medicines flowing smoothly. The new quotas take effect right away on November 10, 2026, so manufacturers can ramp up production without delay.
Previous / Next Documents
Previous: 2026-19791, Denial of Motor Vehicle Defect Petition, DP26-005
NHTSA has decided not to investigate claims about airbags accidentally deploying in 2011-2017 Honda Odyssey vehicles. After checking complaints and data, they found no safety defect that needs fixing. If you own one of these vehicles, no recalls or repairs are coming, so no extra costs or changes for now.
Next: 2026-19793, Request Notice: Use of Foreign-Built Small Passenger Vessel in United States Coastwise Trade, S/V SUZIE MANUELA
The Maritime Administration is asking for public comments on whether a foreign-built small passenger vessel, the S/V SUZIE MANUELA, should be allowed to operate in U.S. coastal trade. This decision could affect U.S. shipbuilders and businesses using American-made vessels. Comments are due by October 28, 2026, so don’t miss your chance to weigh in!